Latest News

Over the past week, Bayer announced a slate of healthcare advances, including new clinical trials in rare kidney disease and women’s health, regulatory submissions for its imaging contrast agent gadoquatrane, and expanded U.S. clearance for its MEDRAD Centargo CT injector. Together, these moves highlight how Bayer is leaning on its pharmaceuticals and medical imaging pipeline to refresh growth drivers while addressing meaningful unmet medical needs. We’ll now explore how Bayer’s push into...

Concentra Group Holdings Parent recently opened Concentra Corona, a new occupational health medical center at 629 North Main Street, Unit C-3, Corona, California, offering work injury care, physical therapy, drug testing, DOT physicals, pre-placement exams, and employer-focused telemedicine services. This expansion deepens Concentra’s California footprint and highlights how its proprietary Concentra Telemed platform is being integrated alongside brick‑and‑mortar clinics to support employer...

If you have ever wondered whether PepsiCo is quietly turning into a value opportunity or just a steady dividend name at a fair price, you are exactly who this breakdown is for. PepsiCo's share price has drifted lately, slipping 2.3% over the last week and down 4.1% over the past year, even though it is still up 16.5% over five years. This mix hints at shifting market expectations rather than a broken story. Recent headlines have focused on PepsiCo's continued push into higher margin snacks...

Unum Group (UNM) just put a fresh $1 billion share repurchase program on the table, a move that signals management sees potential value in the stock and intends to continue returning cash to shareholders. See our latest analysis for Unum Group. That confidence is playing out against a steadier price backdrop, with the latest share price at $73.38 and a modestly negative 90 day share price return. At the same time, a powerful three year total shareholder return of around 102% suggests longer...

If you are wondering whether PNC Financial Services Group at around $202 a share is still good value, or if the easy gains are already behind it, you are not alone. That is exactly what this breakdown is here to unpack. The stock has climbed 2.1% over the last week and 9.2% in the past month, building on a 52.5% gain over three years and 66.7% over five years. This naturally raises the question of how much upside might be left. Recent moves have been shaped by a steadier outlook for interest...

Recently, Clorox outlined weak expectations for fiscal 2026, projecting a 6–10% sales decline and 21% earnings per share drop, while emphasizing its ongoing digital transformation and product innovation efforts as longer-term growth drivers. An interesting angle is that investors appear focused on the company’s multi-year digital overhaul and new product pipeline, viewing these initiatives as potential value creators despite the near-term pressure on performance. With management highlighting...

Asante Gold has completed construction and commissioning of the new sulphide treatment plant at the Bibiani Gold Mine in Ghana, with continuous 24-hour operations now established and gold recovery rising from about 60% to above 90% following the December 3, 2025 start-up of its oxygen plant and Aachen Reactor. This ramp-up, combined with processing higher-grade ore and a push toward 4.0 million tonnes per year capacity, marks a material shift in Bibiani’s production profile and process...

If you are wondering whether Alphatec Holdings at around $20.67 is still a smart buy after its huge run, or if the easy money has already been made, you are not alone. The stock has slipped 2.6% over the last week but is still up 2.1% over 30 days, with an eye catching 128.1% gain year to date and 113.3% over the past year. This naturally raises questions about how much upside is left. Investors have been reacting to a stream of positive updates around Alphatec's expanding spine surgery...

In early December 2025, BioNTech and its partners OncoC4 and Bristol Myers Squibb reported past trial data showing that their experimental cancer therapies gotistobart and pumitamig improved outcomes versus standard care in difficult-to-treat lung and triple-negative breast cancers, with manageable safety profiles and ongoing Phase 3 programs. These oncology readouts suggest BioNTech’s pipeline is starting to yield clinically meaningful assets in high-need solid tumors, potentially...

Endeavour Silver (TSX:EDR) just closed a $300 million offering of senior unsecured convertible notes due 2031, a material financing move that gives the miner fresh flexibility to fund growth or tidy up its balance sheet. See our latest analysis for Endeavour Silver. The $300 million notes come after a powerful run, with a roughly 45% 90 day share price return and a near doubling of one year total shareholder return. This suggests momentum investors are leaning into Endeavour Silver’s growth...

Earlier this week, Wolters Kluwer Tax & Accounting Germany launched SteuerSparErklärung Online, a browser-based tax filing platform that uses the AI assistant “Alma” to answer natural-language tax questions, while Wolters Kluwer Health’s Ovid Synthesis was adopted by the American Board of Medical Specialties Portfolio Program as an official quality improvement workflow tool. Together, these moves highlight Wolters Kluwer’s push to embed AI and cloud delivery into everyday professional...

Frontline plc’s 2025 Annual General Meeting on 8 December 2025 approved Richard C. Prince as a new director and backed wide share issuance authority, following the US$290 million sale of its five oldest VLCCs and fleet growth to 84 vessels after acquiring 24 VLCCs from Euronav. This combination of board refresh and large-scale asset rotation highlights Frontline’s move toward a younger, more flexible tanker fleet that could influence capital allocation choices. Next, we’ll explore how...

NuScale Power’s small modular reactor ambitions gained traction recently as partner ENTRA1 Energy secured an agreement to deploy up to 6 gigawatts of nuclear capacity with the Tennessee Valley Authority across seven U.S. states, even as Fluor signalled plans to exit its NuScale stake in 2026. This combination of a large-scale deployment pathway and a future shift in the shareholder base highlights both growing commercial interest and evolving ownership risks for NuScale’s still‑unproven...

Fujitsu (TSE:6702) just pulled back the curtain on a multi AI agent collaboration platform for supply chains, with real world trials starting in 2026, and investors are already weighing what this means for long term growth. See our latest analysis for Fujitsu. The announcement sits against a backdrop of strong momentum, with a roughly 47 percent year to date share price return and a 5 year total shareholder return above 200 percent signaling that investors are backing Fujitsu's AI driven...

In early December 2025, Recursion Pharmaceuticals reported past Phase 1b/2 TUPELO trial data showing its investigational drug REC-4881 reduced polyp burden in most familial adenomatous polyposis patients, with rapid and durable effects even after treatment stopped. This early success is being seen as a proof point for Recursion’s AI-enabled drug discovery platform, raising questions about how validated clinical data could reshape perceptions of a business often lumped in with meme stocks...

Wondering if Abercrombie & Fitch is still a bargain after its big run, or if the easy money has already been made? You are not alone; this stock has been firmly on value hunters' radars. Despite slipping about 0.2% over the last week, the share price has surged roughly 39.7% in the past month. Longer term returns are mixed, with a 332.5% gain over 3 years but a 27.7% drop over the last year. Recently, the market has been reacting to Abercrombie & Fitch's ongoing brand reinvention and...

If you have been wondering whether Popular is still a buy after its big multi year run, you are not alone. This article will walk through what the current share price is really baking in. The stock has slipped about 0.6% over the last week but remains up 1.0% over the past month, with a strong 25.7% gain year to date and a hefty 142.7% return over five years that suggests the market has steadily been repricing its prospects. Recent headlines have focused on Popular's positioning in Puerto...

Santacruz Silver Mining (TSXV:SCZ) just set a key catalyst in motion, approving a 1 for 4 share consolidation in order to meet Nasdaq listing requirements and potentially reshape how global investors access the stock. See our latest analysis for Santacruz Silver Mining. The consolidation comes on the back of a powerful run, with a roughly 57 percent 1 month share price return and a 920 percent year to date share price return at a last close of 12.24. The 1 year total shareholder return of...

Interest in Baxter International (BAX) has spiked after a wave of class action lawsuits and an FDA Class I recall tied to its Novum IQ Large Volume Pump. This has raised fresh questions about risk, liability, and long term earnings power. See our latest analysis for Baxter International. Those legal and recall headlines have landed on a stock that was already under pressure, with a steep year to date share price return decline and a deeply negative five year total shareholder return,...

If you have been wondering whether Concentrix is a beaten down bargain or a value trap, you are not alone. This article will walk through the numbers in plain English. The stock has bounced recently, up 3.2% over the last week and 10.4% over the past month, even though it is still down 12.5% year to date and 11.3% over the last year. Over a longer horizon, it has seen a much steeper 67.8% slide over three years and 59.0% over five. That kind of whiplash performance has been shaped by...

Ares Management has already been added to the S&P 500 index, replacing Kellanova after its pending acquisition by Mars prompted the benchmark’s latest reshuffle. Ares also unveiled “Marq Logistics,” uniting more than 600 million square feet of global logistics real estate under a single brand following its GLP Capital Partners acquisition outside China, underscoring its expanding real assets footprint. We’ll now examine how S&P 500 inclusion, and the broader institutional attention it...

Wondering if Antero Midstream is still a good buy after its run up, or if most of the easy money has already been made? In this article, we break down what the market is really pricing in here. The stock has climbed to around $18.58, delivering roughly 4.6% over the last week, 4.9% over the past month, 20.0% year to date and 30.5% over the last year, with a 109.6% gain over three years and 235.0% over five years. Those moves have come as midstream energy names like Antero have benefited from...

In early December 2025, Ameriflex announced a partnership to become Aflac's administrative partner for consumer-directed health (CDH) services in the U.S. public sector, initially covering spending accounts such as Flexible Spending Accounts and Health Savings Accounts alongside Aflac's supplemental insurance offerings. This move highlights Aflac's effort to broaden its role from purely supplemental insurance into integrated benefits administration, aiming to improve operational efficiency...

Münchener Rückversicherungs-Gesellschaft in München (XTRA:MUV2) has just reported fresh progress on its ongoing share buyback, detailing another batch of repurchases that nudges the total past 2.68 million shares. See our latest analysis for Münchener Rückversicherungs-Gesellschaft in München. The buyback update lands against a backdrop of steady gains, with a roughly 10 percent year to date share price return and a powerful 5 year total shareholder return of about 168 percent, signalling...